News | March 24, 2010

Study of ICD Anti-Bacterial Envelope Begins


March 24, 2010 – Enrollment began this week in the CITADEL, which is the second of two large-scale, prospective, multicenter studies comparing implantable electrophysiology device infection rates. The study will look at patients with and without a new anti-bacterial envelope covering their devices.

CITADEL will enroll 2,300 patients at over 50 clinical study sites across the United States. Each patient is currently implanted with a pacemaker, implantable cardioverter-defibrillator (ICD) or a cardiac resynchronization therapy (CRT) device, which will be replaced with an ICD accompanied by AIGISRx. This patient population will be compared to a group of published control patients who have also undergone a pacemaker, ICD or CRT device replacement with an ICD without AIGISRx. The primary endpoints will be major ICD device-related infection and ICD device mechanical complication. Patients will be followed for 12 months, with pre-defined interim analyses at three and six months.

The first study, CENTURION, enrolled its first patient in January. CENTURION is a prospective, multicenter, monitored registry that will enroll 2,000 patients at more than 50 clinical study sites across the country. Each patient is currently implanted with a pacemaker, ICD or CRT device, which will be replaced with a CRT device accompanied by AIGISRx. This patient population will be compared to 2,000 case-matched controls that have also undergone a pacemaker, ICD or CRT device replacement with a CRT without AIGISRx. The primary endpoints will be major CRT device-related infection and CRT device mechanical complication. Patients will be followed for 12 months, with predefined interim analyses at three and six months.

AIGISRx is an anti-bacterial mesh envelope developed to deliver anti-microbial agents that help provide protection against infections associated with implanted pacemakers and cardioverter defibrillators. AIGISRx also securely holds a pacemaker or ICD in order to create a stable environment when implanted in the body.

“Device implanters are keenly aware of the risk of pocket infections, especially in patients with underlying health conditions,” Ibrahim Hanna, M.D., director of cardiac electrophysiology at Cardiology PC and Princeton Baptist Medical Center, Birmingham, Ala. “To date our ability to impact this issue has been limited. We are excited about the prospect of testing a simple, intuitive, and potentially highly effective approach to the problem. The TYRX antibacterial envelope is placed around the device and leads and left in the pocket allowing a cocktail of antibiotics to elute over seven days. We have enrolled our first patient in CITADEL and found the envelope very simple to use. It did not add any significant time or risk to the procedure and the whole process went very smoothly.

CENTURION and CITADEL are registered in the ClinicalTrials.gov registry of federally and privately supported clinical trials conducted in the United States and around the world (www.ClinicalTrials.gov).

For more information, please visit www.TYRX.com


Related Content

News | Pacemakers

March 26, 2024 — UC San Diego Health is the first health system in San Diego to successfully implant the world’s first ...

Home March 26, 2024
Home
News | Pacemakers

March 15, 2024 — Following the recent CE approval of the Solia S lead1 for LBBAP, BIOTRONIK proudly announces the world ...

Home March 15, 2024
Home
News | Pacemakers

March 15, 2024 — Following the recent CE approval of the Solia S lead1 for LBBAP, Biotronik announces the world’s first ...

Home March 15, 2024
Home
News | Pacemakers

January 5, 2024 — Medtronic, a global leader in healthcare technology, today announced it has received CE (Conformité ...

Home January 05, 2024
Home
News | Pacemakers

August 21, 2023 — The first implant in Europe of Biotronik’s latest pacemaker and CRT-P generation was conducted in ...

Home August 21, 2023
Home
News | Pacemakers

July 6, 2023 — BIOTRONIK announced U.S. Food and Drug Administration (FDA) approval of its portfolio of Amvia Edge ...

Home July 06, 2023
Home
News | Pacemakers

July 5, 2023 — Abbott announced that the U.S. Food and Drug Administration (FDA) has approved the AVEIR dual chamber (DR ...

Home July 05, 2023
Home
News | Pacemakers

June 1, 2023 — Every year more than one million people receive a pacemaker. Until now, leadless versions were only ...

Home June 01, 2023
Home
News | Pacemakers

May 25, 2023 — Abbott announced late-breaking results from the AVEIR dual-chamber (DR) i2i Investigational Device ...

Home May 25, 2023
Home
News | Pacemakers

May 12, 2023 — Biotronik, a leading global medical technology company with 60 years of experience in developing trusted ...

Home May 12, 2023
Home
Subscribe Now